Roche launches Discovery Green HRP kit
June 2021—Roche launched its Discovery Green horseradish peroxidase (HRP) kit, to identify and profile biomarkers and cell populations in tissue-based research.
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Bio-Techne to acquire Asuragen
June 2021—Bio-Techne Corp. has reached an agreement to acquire Asuragen for initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones.
FDA expands EUA for TaqPath COVID-19 combo kit
June 2021—Thermo Fisher Scientific announced the FDA has expanded emergency use authorization for the Applied Biosystems TaqPath COVID-19 Combo Kit to include the high-throughput Thermo Fisher Scientific Amplitude solution.
Study highlights benefits of T2MR technology
June 2021—T2 Biosystems announced that Expert Review of Medical Devices published meta-analysis findings confirming that using the company’s magnetic resonance (T2MR) technology for identification of bloodstream infections provides faster time to detection, faster transition to targeted microbial therapy, faster de-escalation of empirical therapy, and shorter intensive care unit and hospital stay, and with comparable mortality rate versus the current blood culture standard (Giannella M, et al. Online ahead of print April 16, 2021. doi:10.1080/17434440.2021.1919508). Study authors systematically searched Medline, Embase, and Cochrane Central Register of Controlled Trials for randomized trials or observational controlled studies of patients with suspected bloodstream infections receiving a diagnosis with T2MR or blood culture, ultimately including 14 studies.
QIAreach Anti-SARS-CoV-2 Total Test receives EUA
June 2021—Qiagen received emergency use authorization for its QIAreach Anti-SARS-CoV-2 Total Test, a digital assay to detect total SARS-CoV-2 antibodies (IgA, IgG, IgM).
Dyad COVID-19 specimen collection kits, components
May 2021—Dyad Enterprise, formed in early 2020 in response to the COVID-19 pandemic, offers customizable COVID-19 kits and components based on specimen type, handling, and shipping requirements. Products include customizable nasopharyngeal and oropharyngeal COVID-19 specimen collection kits as well as saliva collection kits. COVID-19 antigen tests are also available. All products are available for immediate shipment.
Roche launches SARS-CoV-2 variant test
May 2021—Roche launched the Cobas SARS-CoV-2 Variant Set 1 Test to detect and differentiate mutations found in variants that originated in the U.K. (B.1.1.7), South Africa (B.1.351), and Brazil (P.1). This research use only laboratory test can be used to help scientists track mutation prevalence and to assess potential impact on diagnostics, vaccines, and therapeutics.
Seegene submits EUA for SARS-CoV-2 multiplex assay
May 2021—Seegene announced it has submitted its Allplex SARS-CoV-2/FluA/FluB/RSV Assay to the FDA for emergency use authorization.
Thermo Fisher launches customizable SARS-CoV-2 mutation panel
May 2021—Thermo Fisher Scientific launched its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel, with a customizable menu of 22 verified real-time PCR assays for identification of SARS-CoV-2 mutations. The assays enable surveillance of variants that cause COVID-19 infection in specific regions globally and allow laboratories to choose which mutations to track.
Abbott’s Alinity m Resp-4-Plex gets EUA
May 2021—The FDA granted emergency use authorization for Abbott’s Alinity m Resp-4-Plex molecular assay, which detects and differentiates SARS-CoV-2, influenza A and B, and respiratory syncytial virus in one test. The test is CE marked and available in countries outside the U.S.